You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The FDA last week also reissued an EUA for a PCR-based SARS-CoV-2 test from Quest Diagnostics to permit its use with pooled samples.
Cepheid said that the 4-in-1 test runs on any of almost 30,000 GeneXpert Systems, which provide results in approximately 36 minutes.
The firm's new application of its BCR-ABL test will be able to detect p190 transcripts and is currently for research use only.
The deal comes one week after the Netherlands said it was buying 9.2 million of the tests. The Canadian government is also purchasing 2,172 BD Veritor Plus Systems.
The revenue increase was driven by significant growth in the conglomerate's life sciences segment.
With nearly 7 million COVID-19 cases, the country is expanding near-patient strategies historically deployed for tuberculosis testing for SARS-CoV-2 testing.
The test runs on multiple GeneXpert systems and tests nasopharyngeal and nasal swabs or nasal wash/aspirate specimens.
Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.
A SNP in the pan-SARS E gene has not affected patient results, but has raised concerns about the overall unavailability of commercial primer and probe information.
The coming uptick in flu and other respiratory viruses will likely complicate the diagnosis of COVID-19 even as labs continue to struggle with capacity.